The outcome and safety of re-challenge Lutetium-177 PSMA (177Lu-PSMA) therapy with Low-Dose Docetaxel as a Radiosensitizer—a promising combination in metastatic castrate-resistant prostate cancer (mCRPC) : a case report

Please note, we are experiencing high volume submissions; you will receive confirmations of submissions in due course. Data upload (DOI): https://researchdata.up.ac.za/ UPSpace: https://repository.up.ac.za/handle/2263/51914

Files in this item

This item appears in the following Collection(s)